Amoena Management Holding GmbH has secured refinancing to bolster its position as a global leader in silicone breast prostheses and postoperative care products.

Target Information

Amoena Management Holding GmbH, founded in 1975, is a leading provider of medical breast care products worldwide. Headquartered in Raubling, Bavaria, the company employs over 375 individuals globally. Amoena specializes in serving breast cancer patients who have undergone partial or complete mastectomies, offering the broadest portfolio of medically certified products available in the market, including silicone breast prostheses and postoperative care products. Recently, they have expanded their offerings to include lymph products for breast care and a variety of medical specialty clothing.

After introducing the world's first silicone-filled breast prosthesis, Amoena has established itself as a leader in quality and innovation within the healthcare sector.

Industry Overview

The healthcare industry in Germany is characterized by its advanced infrastructure and innovative medical technologies. With a strong emphasis on research and development, Germany remains at the forefront of healt

View Source

Similar Deals

Blue Owl Capital ITM Isotope Technologies Munich SE

2025

Venture Debt Proprietary & Advanced Pharmaceuticals Germany
European Investment Bank Smart Reporting

2023

Venture Debt Healthcare Facilities & Services (NEC) Germany
GF BRYCK Ventures 2NA FISH GmbH

2026

Pre-Seed Stage Bio Diagnostics & Testing Germany
Novalis Biotech Altavo GmbH

2026

Series A Advanced Medical Equipment & Technology (NEC) Germany
Demant KIND

2026

Other Medical Equipment, Supplies & Distribution (NEC) Germany
Verdane Clue

2026

Growth Equity & Expansion Capital Healthcare Facilities & Services (NEC) Germany

Apera and OLB

invested in

Amoena Management Holding GmbH

in 2025

in a Venture Debt deal

Deal Parameters
Industry
Country
Seller type

Sign Up to Dealert